Last reviewed · How we verify

Exidine (CHLORHEXIDINE)

Molnlycke Hlth · FDA-approved withdrawn Small molecule Quality 45/100

Chlorhexidine (Exidine), marketed by Molnlycke Health, is a leading antiseptic solution primarily used for healthcare personnel hand hygiene. Its key strength lies in its mechanism of action, which effectively disrupts bacterial cell membranes, leading to cell death, providing robust protection against a wide range of pathogens. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics and other antiseptics in the same class, such as hydrogen peroxide and neomycin.

At a glance

Generic nameCHLORHEXIDINE
SponsorMolnlycke Hlth
Drug classchlorhexidine
TargetSolute carrier family 22 member 1
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved
First approval1976

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: